Trethera and UCLA Publish Comprehensive Review Highlighting Deoxycytidine Kinase as a Novel Metabolic Target for Cancer Therapy
Trethera Announces Massachusetts General Hospital Clinical Trial Collaboration to Evaluate TRE-515 in ALS Patients
Trethera to Highlight Clinical Momentum and Indication Expansion at Biocom Global Partnering & Investor Conference
Trethera Receives $2.7 Million NIH Grant, Validating the Potential of First-in-Class TRE-515 to Overcome KRAS Inhibitor Resistance in Lung Cancer
Trethera Successfully Completes Phase 1 Dose Escalation Trial Demonstrating Broad Therapeutic Window, Favorable Safety, and Confirmed Target Engagement
Trethera Successfully Completes Enrollment of Phase 1 Dose Escalation Trial for Patients with Solid Tumors
Trethera Awarded $2.3 Million NIH Grant to Study TRE-515 Combined with Radiation Therapy in Prostate Cancer Preclinical Models
